Summary
Benjamin Kellman is a biotech founder and glycobiologist with 12 years of interdisciplinary experience bridging bioinformatics, systems biology, and therapeutic protein design. As CEO and co-founder of Augment and a research fellow at the Ragon Institute/Harvard Medical School, he leads development of GlycoTemplating—an expression-agnostic, site-specific glycoengineering platform that encodes glycans into primary protein sequences to improve biologics’ efficacy, safety, and manufacturability. His PhD work in bioinformatics at UC San Diego and postdoctoral training in immunology inform a data-driven approach to glycomics, having contributed novel models for glycan biosynthesis and metabolism across contexts from infant gut health to viral infection. Benjamin blends hands-on algorithm development and wet-lab insight, a combination that helped pioneer big-data glycomics, and he retains a mathematic and computer-science-informed perspective from early work in network inference and protein interactome modeling. Based in Cambridge, MA, he is focused on making glycobiology predictable and programmable for therapeutic impact.
12 years of coding experience
6 years of employment as a software developer
University of California, San Diego
Postdoctoral Fellow Immunology, Postdoctoral Fellow Immunology at Harvard Medical School
Bachelor of Science (B.S.) Neurobiology of Brain and Cognitive Science with distinction, Bachelor of Science (B.S.) Neurobiology of Brain and Cognitive Science with distinction at University of Rochester
English